Compare Quest Diagnostics Inc (DGX) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Simon Property Group Inc — how do they compare? Quest Diagnostics Inc trades at $238.53 (market cap $26.21B), while Simon Property Group Inc trades at $220.44 (market cap $71.03B). The key difference: Simon Property Group Inc is far larger — about 2.7× Quest Diagnostics Inc's market cap, and Simon Property Group Inc pays the higher dividend (4.05%). Which is the better fit depends on your goals.
| DGX | SPG | |
|---|---|---|
Market Cap | $26.21B | $71.03B |
Sector | Health | Real Estate |
52-Week High | $238.50 | $236.70 |
52-Week Low | $173.49 | $169.22 |
Enterprise Value | $31.97B | $99.48B |
Dividend Yield | 1.45% | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Simon Property Group (SPG) trades at $220.37, down 0.08% on the day, with a bearish technical signal but strong fundamentals. Recent Q2 2026 earnings showed an EPS miss ($1.49 actual vs. $1.64 expected), though FFO beat estimates and full-year guidance was raised. The company maintains robust profitability with a net income margin of 66.57% and pays consistent dividends.
Outlook is mixed: solid operational performance and raised guidance support upside near the $226.58 consensus price target, but high debt ($24.21B) and economic sensitivity pose risks. Analyst sentiment leans neutral with 54.05% hold ratings, reflecting cautious optimism amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
